G-CAN endorsed labels and definitions for the disease states of gout (Bursill et al., Ann Rheum Dis 2019;78(11):1592-600)

<table>
<thead>
<tr>
<th>Consensus label</th>
<th>Consensus definition</th>
</tr>
</thead>
</table>

**Preclinical states**

1. **Asymptomatic hyperuricemia†**
   Hyperuricemia† in the absence of gout.

2. **Asymptomatic monosodium urate crystal deposition**
   Evidence of monosodium urate crystal deposition in the absence of gout. Monosodium urate crystal deposition may be demonstrated by imaging or microscopic analysis.

3. **Asymptomatic hyperuricemia† with monosodium urate crystal deposition**
   Hyperuricemia† with evidence of monosodium urate crystal deposition in the absence of gout. Monosodium urate crystal deposition may be demonstrated by imaging or microscopic analysis.

**Clinical states**

4. **Gout**
   A disease caused by monosodium urate crystal deposition with any of the following clinical presentations (current or prior): gout flare, chronic gouty arthritis, or subcutaneous tophus.

5. **Tophaceous gout**
   Gout with at least one subcutaneous tophus.

6. **Erosive gout**
   Gout with at least one gouty bone erosion.

**Disease course states**

7. **First gout flare**
   The first episode of gout flare.

8. **Recurrent gout flares**
   More than one gout flare.

**Additional recommendation on disease states not addressed by the nomenclature**

Where there is more than one disease state present, these can be combined (for example: tophaceous and erosive gout). Where there are additional elements present, not recognized as disease states, these will be labelled as the recognized disease state with or without additional disease elements (for example: tophaceous gout with chronic gouty arthritis).

†In British English, hyperuricaemia.